• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

IL-27抑制小胶质细胞过度激活的作用研究

武陵溪, 杜怡萱, 高向东

武陵溪,杜怡萱,高向东. IL-27抑制小胶质细胞过度激活的作用研究[J]. 中国药科大学学报,2024,55(6):801 − 808. DOI: 10.11665/j.issn.1000-5048.2024022702
引用本文: 武陵溪,杜怡萱,高向东. IL-27抑制小胶质细胞过度激活的作用研究[J]. 中国药科大学学报,2024,55(6):801 − 808. DOI: 10.11665/j.issn.1000-5048.2024022702
WU Lingxi, DU Yixuan, GAO Xiangdong. Inhibitory effect of IL-27 on the overactivation of microglia[J]. J China Pharm Univ, 2024, 55(6): 801 − 808. DOI: 10.11665/j.issn.1000-5048.2024022702
Citation: WU Lingxi, DU Yixuan, GAO Xiangdong. Inhibitory effect of IL-27 on the overactivation of microglia[J]. J China Pharm Univ, 2024, 55(6): 801 − 808. DOI: 10.11665/j.issn.1000-5048.2024022702

IL-27抑制小胶质细胞过度激活的作用研究

基金项目: 国家自然科学基金项目(No.82073755)
详细信息
    通讯作者:

    高向东: Tel:025-83271543 E-mail:xdgao@cpu.edu.cn

  • 中图分类号: R743

Inhibitory effect of IL-27 on the overactivation of microglia

Funds: This study was supported by the National Natural Science Foundation of China (No. 82073755)
  • 摘要:

    小胶质细胞介导的神经炎症对阿尔茨海默病(Alzheimer’s disease,AD)的发生发展至关重要。通过分析GEO数据库,发现IL-27在AD患者大脑皮质和海马中表达均下降。本研究建立了Aβ1-42损伤BV-2细胞的AD细胞模型、脂多糖(LPS)损伤BV-2细胞的炎症细胞模型和炎症动物模型,给予IL-27以评估其对调节小胶质细胞表型和神经炎症的作用。在动物模型中,通过免疫组化检测海马中Iba1+小胶质细胞数量,通过qPCR、ELISA和Western blot检测TNF-α、IL-1β和IL-6等促炎因子表达水平;在细胞模型中,通过qPCR检测小胶质细胞M1/M2表型标志物的表达水平。为进一步探究IL-27的作用机制,通过Western blot检测给予IL-27和Aβ1-42后小胶质细胞中NF-κB、p-NF-κB、IκBα和p-IκBα的表达水平。研究结果表明,IL-27缓解了LPS诱导的脑内小胶质细胞异常激活,降低TNF-α、IL-1β和IL-6等促炎因子表达水平;将 LPS或Aβ1-42诱导的小胶质细胞从神经毒性的M1型转化为神经保护的M2型,改善了Aβ1-42诱导的细胞内NF-κB和IκBα的异常磷酸化水平。本研究提示IL-27可调控Aβ1-42或LPS诱导下的小胶质细胞M1/M2极化,进而缓解神经炎症。

    Abstract:

    Neuroinflammation mediated by microglia is essential for the occurrence and development of Alzheimer’s disease (AD). Through the analysis of the GEO database, it was found that IL-27 expression decreased in both the cerebral cortex and hippocampus of AD patients. In this study, the AD cell model of BV-2 cells injured by Aβ1-42, the inflammatory cell model of BV-2 cells damaged by LPS, and the inflammatory animal model were established and the effects of IL-27 after its administration in the above models in regulating microglial phenotype and neuroinflammation were evaluated. In the animal models, the number of Iba1+ microglia in the hippocampus was detected by immunohistochemistry, the expression of pro-inflammatory factors such as TNF-α, IL-1β and IL-6 was detected by qPCR, ELISA and Western blot, and the expression of M1/M2 phenotypic markers in microglia was detected by qPCR. To further explore the action mechanism of IL-27, Western blot was used to detect the expression levels of NF-κB, p-NF-κB, IκBα and p-IκBα in microglia after administration of IL-27 and Aβ1-42. The results showed that IL-27 alleviated the abnormal activation of microglia induced by lipopolysaccharide (LPS), decreased the expression of pro-inflammatory factors such as TNF- α, IL-1β and IL-6, transformed microglia induced by LPS or Aβ1-42 from neurotoxic M1 to neuroprotective M2, and improved the abnormal phosphorylation of NF-κB and IκBα induced by Aβ1-42. The research suggested that IL-27 can regulate the M1/M2 polarization of microglia induced by Aβ1-42 or LPS, and alleviate neuroinflammation.

  • Figure  1.   Analysis of IL-27 expression in the brains of normal and Alzheimer’s disease(AD) patients. In Hippocampus region, control group n=19, AD group n=19. In the entorhinal cortex region, control group n=19, AD group n=15. In the frontal cortex region, control group n=27, AD group n=21. (ns: no significance vs control group)

    Figure  2.   Effect of IL-27 on activation of microglia in lipopolysaccharide(LPS)-induced mice brain

    A: Expression of Iba1 in the brain of normal mice, LPS-induced inflammation mice, and IL-27 treated mice after LPS-induced inflammation was detected by immunohistochemistry (Scale bar=100 μm); B: Quantitative analysis of Iba1+ levels in A ($\bar{x} $ ± s, n=3, ###P < 0.001 vs control group; **P < 0.01 vs LPS group)

    Figure  3.   Effect of IL-27 on the expression of inflammatory factors in the brain of mice induced by LPS ($\bar{x} $ ± s)

    A: mRNA levels of Il1b, Il6 and Tnf were detected by RT-qPCR; B: Levels of IL-1β, IL-6, TNF-α were detected by ELISA; C: Representative images of the levels of IL-1β, TNF-α were detected by Western blot; D-E: Quantitative analysis of protein levels of TNF-α/actin and IL-1β/actin(n=5 in ELISA, the other n=3) ###P < 0.001, ##P < 0.01 vs control group; ***P < 0.001, **P < 0.01 vs LPS group

    Figure  4.   Effect of IL-27 on mRNA expression of M1/M2 cell markers in LPS-induced microglia ($\bar{x} $ ± s, n=3)

    A: mRNA levels of M1-specific makers Il1b, Tnf, Nos2, Nlrp3, Fcgr2b, Cd86 and Fcgr3 were detected by RT-qPCR; B: mRNA levels of M2-specific makers Il10, Chil3 and Arg1 were detected by RT-qPCR ###P < 0.001, ##P < 0.01, #P < 0.05 vs control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs LPS group

    Figure  5.   Effect of IL-27 on mRNA expression of M1/M2 cell markers in Aβ1-42-induced microglia ($\bar{x} $ ± s, n=3)

    A: mRNA levels of M1-specific makers Il1b, Tnf, Nlrp3 and Nos2 were detected by RT-qPCR; B: mRNA levels M2-specific makers of Il10, Chil3 and Arg1 were detected by RT-qPCR ###P < 0.001, ##P < 0.01, #P < 0.05 vs control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs1-42 group

    Figure  6.   Effect of IL-27 on activation of NF-κB, p-NF-κB, IκBα, and p-IκBα in microglia induced by Aβ1-42

    A: Levels of NF-κB, p-NF-κB, IκBα and p-IκBα were detected by Western blot; B-C: Quantitative analysis of protein levels of p-NF-κB/NF-κB and p-IκBα/ IκBα in A (`x ± s, n=3, ###P < 0.001, ##P < 0.01, #P < 0.05 vs control group; ***P < 0.001, **P < 0.01, *P < 0.05 vs1-42 group)

    Table  1   Primer sequences for RT- PCR

    Biological indicator Forward primer (5'→3') Reverse primer (5'→3')
    TnfTTGGTGGTTTGTGAGTGTGAGGACGTGGAACTGGCAGAAGAG
    Il6TTGGTCCTTAGCCACTCCTTTAGTCCTCCTACCCCAATT
    Il1bATCTTTTGGGGTCCGTCAACTGCAACTGTTCCTGAACTCAACT
    Nos2GTGGACGGGTCGATGTCACGTTCTCAGCCCAACAATACAAA
    Nlrp3ACAAGCCTTTGCTCCAGACCCTATTGCTCTTCACTGCTATCAAGCCCT
    Fcgr2bGGGAACCAATCTCGTAGTGTCTGTCCAGAAAGGCCAGGATCTAGTG
    Cd86GAGCGGGATAGTAACGCTGAGGCTCTCACTGCCTTCACTC
    Fcgr3GTCCAGTTTCACCACAGCCTTCGCCAATGGCTACTTCCACCAC
    Chil3GGGCATACCTTTATCCTGAGCCACTGAAGTCATCCATGTC
    Il10GGTTGCCAAGCCTTATCGGAACCTGCTCCACTGCCTTGCT
    Arg1GTGAAGAACCCACGGTCTGTCTGGTTGTCAGGGGAGTGTT
    ActbAGCCATGTACCTAGCCATCCTTTGATGTCACGCACGATTT
    下载: 导出CSV
  • [1]

    Nayak D, Roth TL, McGavern DB. Microglia development and function[J]. Annu Rev Immunol, 2014, 32: 367-402. doi: 10.1146/annurev-immunol-032713-120240

    [2]

    Lull ME, Block ML. Microglial activation and chronic neurodegeneration[J]. Neurotherapeutics, 2010, 7(4): 354-365. doi: 10.1016/j.nurt.2010.05.014

    [3]

    Fernando KKM, Wijayasinghe YS. Sirtuins as potential therapeutic targets for mitigating neuroinflammation associated with Alzheimer’s disease[J]. Front Cell Neurosci, 2021, 15: 746631. doi: 10.3389/fncel.2021.746631

    [4]

    Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes[J]. Transl Neurodegener, 2020, 9(1): 42. doi: 10.1186/s40035-020-00221-2

    [5]

    Bachiller S, Jiménez-Ferrer I, Paulus A, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response[J]. Front Cell Neurosci, 2018, 12: 488.

    [6]

    Wang CC, Zong S, Cui XL, et al. The effects of microglia-associated neuroinflammation on Alzheimer’s disease[J]. Front Immunol, 2023, 14: 1117172. doi: 10.3389/fimmu.2023.1117172

    [7]

    Wolf SA, Boddeke HW, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79: 619-643. doi: 10.1146/annurev-physiol-022516-034406

    [8]

    Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms[J]. Nat Rev Neurosci, 2007, 8(1): 57-69. doi: 10.1038/nrn2038

    [9]

    Udeochu JC, Shea JM, Villeda SA. Microglia communication: parallels between aging and Alzheimer’s disease[J]. Clin Exp Neuroimmunol, 2016, 7(2): 114-125. doi: 10.1111/cen3.12307

    [10]

    Stumhofer JS, Hunter CA. Advances in understanding the anti-inflammatory properties of IL-27[J]. Immunol Lett, 2008, 117(2): 123-130. doi: 10.1016/j.imlet.2008.01.011

    [11]

    Luo C, Li BR, Chen L, et al. IL-27 protects the brain from ischemia-reperfusion injury via the gp130/STAT3 signaling pathway[J]. J Mol Neurosci, 2021, 71(9): 1838-1848. doi: 10.1007/s12031-021-01802-0

    [12]

    Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells[J]. Immunity, 2002, 16(6): 779-790. doi: 10.1016/S1074-7613(02)00324-2

    [13]

    Zhao XR, Ting SM, Liu CH, et al. Neutrophil polarization by IL-27 as a therapeutic target for intracerebral hemorrhage[J]. Nat Commun, 2017, 8(1): 602. doi: 10.1038/s41467-017-00770-7

    [14]

    Xu M, Zhang DF, Luo RC, et al. A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer’s disease[J]. Alzheimers Dement, 2018, 14(2): 215-229. doi: 10.1016/j.jalz.2017.08.012

    [15]

    Alzahrani NA, Bahaidrah KA, Mansouri RA, et al. Investigation of the optimal dose for experimental lipopolysaccharide-induced recognition memory impairment: behavioral and histological studies[J]. J Integr Neurosci, 2022, 21(2): 49. doi: 10.31083/j.jin2102049

    [16]

    Yang L, Zhou RY, Tong Y, et al. Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation[J]. Neurobiol Dis, 2020, 140: 104814. doi: 10.1016/j.nbd.2020.104814

    [17]

    Gu SM, Lee HP, Ham YW, et al. Piperlongumine improves lipopolysaccharide-induced amyloidogenesis by suppressing NF-KappaB pathway[J]. Neuromolecular Med, 2018, 20(3): 312-327. doi: 10.1007/s12017-018-8495-9

    [18]

    Vandenbark AA, Offner H, Matejuk S, et al. Microglia and astrocyte involvement in neurodegeneration and brain cancer[J]. J Neuroinflammation, 2021, 18(1): 298. doi: 10.1186/s12974-021-02355-0

    [19]

    Sowrirajan B, Saito Y, Poudyal D, et al. Interleukin-27 enhances the potential of reactive oxygen species generation from monocyte-derived macrophages and dendritic cells by induction of p47phox[J]. Sci Rep, 2017, 7: 43441. doi: 10.1038/srep43441

    [20]

    Nortey AN, Garces KN, Hackam AS. Exploring the role of interleukin-27 as a regulator of neuronal survival in central nervous system diseases[J]. Neural Regen Res, 2022, 17(10): 2149-2152. doi: 10.4103/1673-5374.336134

    [21]

    Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions[J]. Alzheimers Dement, 2016, 12(6): 719-732. doi: 10.1016/j.jalz.2016.02.010

    [22]

    McNamara AJ, Danthi P. Loss of IKK subunits limits NF-κB signaling in reovirus-infected cells[J]. J Virol, 2020, 94(10): e00382-e00320.

    [23]

    Sun E, Motolani A, Campos L, et al. The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer’s disease[J]. Int J Mol Sci, 2022, 23(16): 8972. doi: 10.3390/ijms23168972

  • 期刊类型引用(3)

    1. 曾雪亮,钟文敏,李蓓. 异甘草酸镁联合疗法治疗慢性乙型肝炎的效果及安全性的meta分析. 中国当代医药. 2021(30): 13-17 . 百度学术
    2. 高华,何海妮,刘莉娜. 异甘草酸镁注射液对耐多药结核鼠T淋巴细胞亚群及血清抗体的影响. 临床和实验医学杂志. 2020(22): 2382-2385 . 百度学术
    3. 柏杰. 双环醇联合异甘草酸镁治疗失代偿期肝硬化疗效观察. 智慧健康. 2020(31): 115-116 . 百度学术

    其他类型引用(1)

图(6)  /  表(1)
计量
  • 文章访问数:  105
  • HTML全文浏览量:  27
  • PDF下载量:  20
  • 被引次数: 4
出版历程
  • 收稿日期:  2024-02-26
  • 刊出日期:  2024-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭